Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment
Mary Hongying Cheng, James Krieger, Burak Kaynak, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 69

Showing 26-50 of 69 citing articles:

E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies
Wei Bu Wang, Yu Liang, Yu Jin, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 26
Computational decomposition reveals reshaping of the SARS‐CoV‐2–ACE2 interface among viral variants expressing the N501Y mutation
Eileen Socher, Marcus Conrad, Lukas Heger, et al.
Journal of Cellular Biochemistry (2021) Vol. 122, Iss. 12, pp. 1863-1872
Open Access | Times Cited: 22
Why are some coronavirus variants more infectious?
Raju Mukherjee, Rohit Satardekar
Journal of Biosciences (2021) Vol. 46, Iss. 4
Open Access | Times Cited: 22
Detection of Major SARS-CoV-2 Variants of Concern in Clinical Samples via CRISPR-Cas12a-Mediated Mutation-Specific Assay
Yuanhao Liang, Lirong Zou, Hongqing Lin, et al.
ACS Synthetic Biology (2022) Vol. 11, Iss. 5, pp. 1811-1823
Closed Access | Times Cited: 15
Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations
Damiano Buratto, Abhishek Saxena, Qun Ji, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 19
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination
Pinja Jalkanen, Pekka Kolehmainen, Anu Haveri, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 2
Open Access | Times Cited: 13
Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor
Khue Vu Nguyen
Nucleosides Nucleotides & Nucleic Acids (2021) Vol. 40, Iss. 6, pp. 665-706
Open Access | Times Cited: 18
UnCoVar: a reproducible and scalable workflow for transparent and robust virus variant calling and lineage assignment using SARS-CoV-2 as an example
Alexander Thomas, Thomas Battenfeld, Ivana Kraiselburd, et al.
BMC Genomics (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants
Efi Makdasi, Anat Zvi, Ron Alcalay, et al.
Cell Reports (2021) Vol. 36, Iss. 10, pp. 109679-109679
Open Access | Times Cited: 15
Point mutations in SARS-CoV-2 variants induce long-range dynamical perturbations in neutralizing antibodies
Dhiman Ray, Riley N. Quijano, Ioan Andricioaei
Chemical Science (2022) Vol. 13, Iss. 24, pp. 7224-7239
Open Access | Times Cited: 11
Global Prevalence of Adaptive and Prolonged Infections’ Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein
Johan Lennerstrand, Navaneethan Palanisamy
Viruses (2021) Vol. 13, Iss. 10, pp. 1974-1974
Open Access | Times Cited: 12
Targeted Sanger sequencing to recover key mutations in SARS-CoV-2 variant genome assemblies produced by next-generation sequencing
Lavanya Singh, James Emmanuel San, Houriiyah Tegally, et al.
Microbial Genomics (2022) Vol. 8, Iss. 3
Open Access | Times Cited: 9
Structural Analysis of Spike Protein Mutations in the SARS-CoV-2 P.3 Variant
Neil Andrew D. Bascos, Denise Mirano‐Bascos, Cynthia P. Saloma
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 11
Landscape-Based Mutational Sensitivity Cartography and Network Community Analysis of the SARS-CoV-2 Spike Protein Structures: Quantifying Functional Effects of the Circulating D614G Variant
Gennady M. Verkhivker, Steve Agajanian, Deniz Yaşar Öztaş, et al.
ACS Omega (2021) Vol. 6, Iss. 24, pp. 16216-16233
Open Access | Times Cited: 11
From Free Binding Energy Calculations of SARS-CoV-2—Receptor Interactions to Cellular Immune Responses
Michael O. Glocker, Kwabena F.M. Opuni, Hans‐Juergen Thiesen
Medicina (2022) Vol. 58, Iss. 2, pp. 226-226
Open Access | Times Cited: 8
Epidemiological and clinical presentations of hospitalized COVID-19 patients in Libya: An initial report from Africa
Muhammed Elhadi, Ahmed Abdulhakim Momen, Ahmed Alsoufi, et al.
Travel Medicine and Infectious Disease (2021) Vol. 42, pp. 102064-102064
Open Access | Times Cited: 10
Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2’s pathogenicity factors
Ömür Baysal, Naeem Abdul Ghafoor, Ragıp Soner Silme, et al.
PLoS ONE (2021) Vol. 16, Iss. 5, pp. e0252571-e0252571
Open Access | Times Cited: 9
Rapid increase of SARS-CoV-2 variant B.1.1.7 detected in sewage samples from England between October 2020 and January 2021
Thomas Wilton, Erika Bujáki, Dimitra Klapsa, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 8
Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization
Yunjeong Kim, Natasha N. Gaudreault, David A. Meekins, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 8
Antibody–nanobody combination increases their neutralizing activity against SARS-CoV-2 and nanobody H11-H4 is effective against Alpha, Kappa and Delta variants
Hung Van Nguyen, Mai Suan Li
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 6
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants
Efi Makdasi, Anat Zvi, Ron Alcalay, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 7
Compared with SARS-CoV2 wild type’s spike protein, the SARS-CoV2 omicron’s receptor binding motif has adopted a more SARS-CoV1 and/or bat/civet-like structure
Michael O. Glocker, Kwabena F.M. Opuni, Hans‐Juergen Thiesen
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 7
Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy
Federica Novazzi, Angelo Genoni, Pietro Giorgio Spezia, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 710-712
Open Access | Times Cited: 6
Could it be that the B.1.1.7 lineage is more deadly?
Chia Siang Kow, Syed Shahzad Hasan
Infection Control and Hospital Epidemiology (2021) Vol. 43, Iss. 5, pp. 678-679
Open Access | Times Cited: 5
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants with a novel competitive multiplex assay
Ester López, Ebene R. Haycroft, Amy Adair, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 5

Scroll to top